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 In 2 different mouse models, AKI increased Gal-3 expression and induced cardiac dysfunction, cardiac and systemic
inflammation, cardiac macrophage infiltration, and fibrosis.
 Cardiac consequences of AKI were dependent on the Gal-3 pathway and were prevented using Gal-3 knockout mice or
modified citrus pectin as a pharmaceutical inhibitor.
 Cardiac Gal-3 expression resulted from bone marrow-derived immune cells recruitment after AKI.
 In critically ill patients, development of AKI is associated with increased plasma Gal-3 levels and increased biomarkers of
cardiac injury and damage.https://doi.org/10.1016/j.jacbts.2019.06.005
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reAcute kidney injury is associated with increased risk of heart failure and mortality. This study demonstrates that
acute kidney injury induces remote cardiac dysfunction, damage, injury, and fibrosis via a galectin-3 (Gal-3)
dependent pathway. Gal-3 originates from bone marrow-derived immune cells. Cardiac damage could
be prevented by blocking this pathway. (J Am Coll Cardiol Basic Trans Science 2019;4:717–32) © 2019 The
Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A cute kidney injury (AKI) has beenassociated with an increased risk ofmortality (1), even in patients free
of previous cardiovascular comorbidities
(2). Furthermore, AKI has been associated
with long-term cardiovascular events (3).
Whether the occurrence of AKI only reflects
the severity and magnitude of underlying
disease or may contribute to remote organ
injury remains uncertain. Remote cardiovas-
cular injury may contribute to poor outcomes
after AKI (4). AKI has also been associated
with long-term cardiovascular events. This
has been described in type 3 cardiorenal syn-
drome (or acute reno-cardiac syndrome) (5).SEE PAGE 733However, whether transient AKI can induce long-
term cardiac injury remains unexplored. Cardiac
fibrosis has been described as a key feature of chronic
heart diseases (6). Galectin-3 (Gal-3) is a lectin that
specifically binds to b-galactosides (7) expressed in
many tissues, including the heart and kidney (8,9).
In the heart, Gal-3 induction promotes myocardial
fibrosis and heart failure progression (10,11). Gal-3
has been shown to be a key player in cardiac fibrosis
induction and has been proposed as a prognostic
biomarker for chronic heart failure (7). In the kidney,
Gal-3 has also been shown to be upregulated after AKI
(12). In the present study, we hypothesized that AKISanté et de la Recherche Médicale (INSERM)” and by Paris D
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ceived February 21, 2019; revised manuscript received May 29can activate Gal-3dependent pathways and promote
cardiac injury. For this purpose, we explored the role
of Gal-3 in cardiac injury after kidney injury. More-
over, a bone marrow (BM) graft from Gal-3 knock-out
(KO) mice was used to determine the origin of Gal-3.METHODS
ANIMALS. Two- to 4-month old male C57Bl6/J mice
(Janvier laboratory, Le Genest-Saint-Isle, France) and
C57Bl6/J KO mice for Galectin-3 [Gal-3 KO (13)] were
used. All animals were randomized into different
groups after baseline echocardiography. Methods of
echocardiography, plasma assays, gene expression
analysis, protein analysis, immunostaining, cardiac
fibrosis evaluation, renal macrophage isolation, cell
culture, and monocyte adhesion assays are detailed
in the Supplemental Appendix.
Renal and h ind l imb ischemia- reperfus ion
in jury . A right nephrectomy and left renal pedicle
occlusion (25 min of ischemia), followed by reperfu-
sion, were performed under anesthesia (intraperito-
neal injection of ketamine: 100 mg/kg and xylazine:
20 mg/kg). Right kidneys were used as controls. Sham
mice underwent the same procedure, except for renal
pedicle occlusion and right nephrectomy (14). To
understand the kinetics of the kidneyheart crosstalk
after renal ischemiareperfusion (IR), mice were kil-
led at different time points after reperfusion (at 3, 6,
12, 24, 48, and 72 h, and at 28 days; n ¼ 7 per group)iderot University and the Société Française d’Anes-
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FIGURE 1 Renal IR Leads to Acute and Transient Renal Dysfunction With Increased Gal-3 Expression
A
B
C
D
(A) Plasma assays performed in sham and ischemiareperfusion IR mice showed an early and transient increase in creatinine and blood urea nitrogen (BUN) levels after
IR compared with sham mice (p < 0.001; wild-type [WT] IR mice vs. WT sham mice). (B) Immunostaining showed increased galectin-3 (Gal-3) expression in kidney
tissue, mainly in tubular cells, in response to renal IR. (C) Quantification of Gal-3 immunostaining of sham, IR 24-h WT, IR 2-h knockout (KO) Gal-3 groups. After IR, Gal-3
expression is increased in WT mice. (D) Gal-3 co-immunostaining with a-smooth muscle actin (SMA) (a marker of smooth muscle cells/myofibroblasts), CD3
(lymphocyte marker), F4/80 (macrophage marker), and GR1 (neutrophil marker) only showed co-localization of Gal-3 with F4/80, indicating that it was also
expressed by infiltrated macrophages within the injured renal tissue after 24 h of IR (white arrows). n ¼ 7 to 14 for WT IR groups; n ¼ 4 to 7 for KO IR; n ¼ 4 for WT and
n ¼ 4 KO Gal-3 sham mice. Data are presented as mean  SEM, and comparisons of medians were made using nonparametric Mann-Whitney U test. *p < 0.05.
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FIGURE 2 Cardiac Inflammation After Renal IR
D
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721(Supplemental Figure 1A). Another mouse group was
submitted to left femoral artery occlusion for 25 min,
followed by reperfusion. These mice were killed
28 days after surgery (hind limb ischemia).
Bone marrow transplantat ion . Mice were irradi-
ated at 10 grays (2  5 grays at 5-h interval) with filter,
with a Faxitron irradiator (Faxitron, Tuscon, Ari-
zona). After the second irradiation, mice were grafted
with BM from wild-type (WT) or KO mice. At the end
of the protocol, 2 groups of chimeric mice were ob-
tained: WT mice grafted with KO Gal-3 bone marrow
(WTKO BM) and KO Gal-3 mice grafted with WT bone
marrow (KOWT BM). These chimeric mice were sub-
mitted to right nephrectomy and left renal IR injury,
as described previously. Sham mice underwent the
same procedure, except for right nephrectomy and
left renal IR (Supplemental Figures 1B and 2).
Uni la tera l uretera l obst ruct ion . A left ureteral
obstruction was performed under anesthesia. The
ureter was subsequently ligated in 2 places near the
kidney. Sham mice underwent the same procedure,
except for ureteral obstruction (Supplemental
Figure 1C).
TREATMENTS. The Gal-3 inhibitor modified citrus
pectin (MCP) was dissolved in drinking water
(100 mg/kg/day). Mice were either pre-treated with
MCP (IRþMCP) 3 days before surgery and during the
time of reperfusion or treated 1 day after surgery
(IRþMCP dþ1).
HUMAN COHORT. The association among AKI, Gal-3,
and cardiac injury was explored in the FROG-ICU
(French and European Outcome Registry in Inten-
sive Care Units) (NCT01367093). This study was an
international observational study that included
consecutive critically ill patients admitted to 23
intensive care units (ICUs) who received mechanical
ventilation and/or vasopressors. The protocol was
previously described elsewhere (15). In thisFIGURE 2 Continued
(A) Superposition of Gal-3 mRNA expression kinetics in the kidney and he
vs. 0 h), which preceded similar observations in the heart (p < 0.001; 4
result, and increased cardiac Gal-3 levels were observed at 72 h compar
after IR. (D) Gal-3 plasma levels began to increase at 48 h after IR compa
WT IR mice vs. WT sham mice), and remained higher for 28 days compar
mice (p < 0.001). (E) Cardiac CD68 mRNA increased at 48 h in WT IR mic
in Gal-3 KO mice (p ¼ 0.03). (F) CD68 immunostaining revealed positive
Quantification confirmed increased Gal-3 expression in the heart. (G) Cyt
IRþMCP dþ1) and Gal-3 KO mice (sham and IR) showed a significant inc
(TNF)-a levels at 6 and 48 h in WT IR mice, compared with WT IRþMCP (
A, n ¼ 4 to 14. For B and C, n ¼ 4 to 7 for the WT and sham groups. For E
MCP, n ¼ 4 to 7 for KO Gal-3 IR. Data are presented as mean  SEM, and
Whitney U test. *p < 0.05. GADPH ¼ glyceraldehyde 3-phosphate dehysubanalysis, patients with chronic kidney disease
were excluded. The study population included 1,110
patients discharged from ICUs with neutrophil
gelatinase-associated lipocalin data available on ICU
admission and Gal-3 data available at ICU discharge.
AKI was defined by the Kidney Disease Improving
Global Outcome (KDIGO) definition (clinical AKI) or
neutrophil gelatinase-associated lipocalin >150 ng/ml
at ICU admission (subclinical AKI) (16,17). Plasmatic
levels of cardiac injury and/or stress biomarkers were
measured at ICU discharge (plasma Gal-3, N-termi-
nalpro-brain natriuretic peptide [NT-proBNP], and
high-sensitivity troponin level). Interleukin (IL)6
was measured as a biomarker of sys-
temic inflammation.
STATISTICAL ANALYSIS. The primary endpoint was
the association between Gal-3 expression and AKI.
Results are expressed as mean  SEM. A nonpara-
metric Mann-Whitney U test was performed, unless
otherwise stated. Levels of Gal-3 at discharge were
compared using the Kruskal-Wallis test in the clinical
cohort. Univariable and multivariable analyses using
propensity score matching assessed the association
between AKI and Gal-3 at ICU discharge in the clinical
cohort. Variables included in the multivariable anal-
ysis were age, hypertension, chronic kidney disease,
atrial fibrillation, liver disease, chronic heart failure,
dyslipidemia, vascular disease, cancer, body mass
index, heart rate, chronic obstructive pulmonary
disease, Charlson score, simplified organ failure
assessment score, simplified acute physiology score
of 2, inotrope use, estimated glomerular filtration rate
(eGFR) (using the Modified and Diet Renal Disease
formula), septic shock, use of red blood cell trans-
fusion, length of stay in the ICU, sex, and arterial
blood pressure. Propensity score matching consid-
ered the probability that a patient with specific
baseline characteristics had an AKI and then allowedart showed an early increase in Gal-3 in the kidney (p < 0.001; 24 h
8 h vs. 6 h). (B) Cardiac Gal-3 protein quantification confirmed this
ed with the sham group (p ¼ 0.016). (C) Kidney Gal-3 protein levels
red with the sham group (p ¼ 0.037), peaked at 72 h (p ¼ 0.017 for
ed with the sham group and modified citrus pectin (MCP)-treated
e (p ¼ 0.017 vs. sham group) and was significantly higher than that
cells at 72 h after reperfusion in IR mice compared with sham mice.
okine assays performed in plasma from WT (sham, IR, IRþMCP and
rease in interleukin (IL)-1-b, IL-6, IL-10, and tumor necrosis factor
p < 0.001), KO IR (p < 0.001), and WT sham mice (p < 0.001). For
and G, n ¼ 4 for sham, n ¼ 7 to 14 for WT IR, n ¼ 7 to12 for WT IR þ
comparisons of medians were made with the nonparametric Mann-
drogenase; other abbreviations as in Figure 1.
FIGURE 3 At 28 Days, Kidney IR-Induced Cardiac Inflammation and Fibrosis Were Prevented in MCP-Treated and Gal-3 KO Mice
A
D
E
B C
(A) Compared with the IR group, Gal-3 KO mice exhibited blunted cardiac inflammatory responses as indicated by lower CD68 mRNA in KO Gal-3 mice (p ¼ 0.007). At
28 days, cardiac expression of Gal-3 remained high versus sham (p ¼ 0.028). Mice treated with MCP had a lower cardiac expression of Gal-3 (p ¼ 0.008 for WT IR vs.
WR IRþMCP, and p ¼ 0.04 for WT IR vs. WT IRþMCP day þ 1 [dþ1] comparisons). (B) Similar results were obtained after cardiac CD68 immunolabeling. CD68þ cells
(green) were present in IR mice, whereas Gal-3 KO and MCP-treated mice showed the minimum CD68þ cells. Cardiac Gal-3 immunolabeling was positive in IR hearts
but negative in treated mice. Quantification of Gal-3 and CD68 immunostainings confirmed the preceding observations (p ¼ 0.012 for WT IR vs. WT IRþMCP and
p < 0.001 for WT IR vs WT IRþMCP dþ1 for CD68 immunostaining comparisons; p < 0.001 for both comparison WT IR vs. IRþMCP and WT IR vs. WT IRþMCP dþ1 for
Gal-3 immunostaining comparisons). (C) Sirius red coloration of the IR hearts treated with MCP (IRþMCP and IRþMCP dþ1) and in Gal-3 KO mice revealed limited cardiac
fibrosis. (D) Computer-assisted cardiac fibrosis evaluation confirmed these results (p < 0.001 for WT sham vs. WT IR and p ¼ 0.003 for WT IR vs. KO Gal-3 IR).
(E) Cardiac function assessed by the analysis of left ventricular fractional shortening (SF) was altered in response to IR (p < 0.001 baseline vs. IR) and rescued in KO-
treated mice (p ¼ 0.002 for IR vs IR þMCP and p < 0.001 for IR vs KO Gal-3). For A to C, n ¼ 5 for sham group, n ¼ 7 to 10 for WT IR, n ¼ 5 to 6 for WT IR þMCP, n ¼ 5
to 6 for WT IR þ MCP dþ1, and n ¼ 5 to 8 for KO Gal-3 IR. For E, n ¼ 43 for baseline echography and n ¼ 7 for other groups. Data are presented as mean  SEM and
comparisons of medians were made with the nonparametric Mann-Whitney U test. *p < 0.05. Abbreviations as in Figures 1 and 2.
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FIGURE 4 Gal-3 From BM-derived Cells, Including Macrophages, Is Sufficient to Induce Cardiac Fibrosis and Dysfunction
A C E
B
G
H
I
D F
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724the comparison of Gal-3 levels in patients with or
without AKI but with similar characteristics. The
propensity score model included age, hypertension,
chronic kidney disease, atrial fibrillation, liver dis-
ease, chronic heart failure, dyslipidemia, vascular
disease, cancer, body mass index, heart rate, chronic
obstructive pulmonary disease, Charlson score,
simplified organ failure assessment score, simplified
acute physiology score of 2, inotrope use, renal
replacement therapy, eGFR (using the Modified and
Diet Renal Disease formula), septic shock at admis-
sion, use of red blood cell transfusion during ICU stay,
length of stay in the ICU, sex, and arterial blood
pressure. Matching was performed according to the
nearest neighbor approach within a caliper width of
0.2 (18). Imbalance between patients with and
without AKI before and after propensity score
matching was assessed using a standardized differ-
ence, considering <10% acceptable to define the
study patients’ characteristics balanced with respect
to the previously described features. All statistical
analyses were performed using R statistical software
version 3.1.1 or above (The “R” Foundation for Sta-
tistical Computing, Vienna, Austria). A p value <0.05
was considered statistically significant.
RESULTS
AKI INDUCES GAL-3 EXPRESSION, CARDIAC INJURY,
AND SYSTEMIC INFLAMMATION. After renal IR in WT
mice, a transient increase in creatinine (Cr) and blood
urea nitrogen (BUN) levels was observed 24 h post-
reperfusion (Figure 1A). Cr and BUN returned to
baseline within 48 h.
AKI induced an increase in kidney Gal-3 expres-
sion, mainly in tubular cells and monocytes at 24 h
(Figures 1B to 1D). The increased expression of Gal-3 in4 Continued
matic assays from chimeric mice WTKO BM mice (WT mice grafted with Gal-3 KO
e marrow) showed a difference in plasmatic Gal-3 level between sham WTKO BM
vel was highly increased at 28 days post-IR in KOWT BM mice compared with s
er at 28 days post-IR (p < 0.001). Gal-3 level was lower in WTKO BM mice com
CD146, monocyte chemoattractant protein (MCP)-1, Gal-3 and intercellular a
nd MCP-1 mRNA expression was higher in IR KOWT BM mice compare with IR
vel did not alter in response to IR, but the level in KOWT BM mice was increase
ration showed an increase in collagen fibers in response to IR in KOWT BM mic
on confirmed these results. (H) Echocardiography revealed a decline in fract
ed in WTKO BM mice (p< 0.001 for IR KOWT BM mice vs. IR WTKO BM mice at 14 an
KOWT BM mice showed CD68þ (green)/Gal-3þ (purple) cells in KOWT BM mice. C
jury. No Gal-3 staining was observed in WTKO BM mice despite CD68þ cells in sh
r sham WTKO BM mice, n ¼ 5 for IR KOWT BM mice, n ¼ 9 for IR WTKO BM mice. Da
ith the nonparametric Mann-Whitney U test. *p < 0.05. Abbreviations as in Fmonocytes was also confirmed in isolated renal
macrophages (Supplemental Figure 3). This increase
was followed by an increase in cardiac Gal-3 expres-
sion at 48 h (Figure 2A), which was confirmed at the
protein level (Figures 2B and 2C). Cardiac tissue infil-
tration by inflammatory cells and systemic inflam-
mation assessed with plasma cytokines and adhesion
molecule levels measurements were observed during
the first 72 h after IR. Plasma levels of Gal-3 increased,
with a peak at 72 h, and remained elevated until day
28 (Figure 2D). CD68 mRNA expression increased in
the heart at 48 h (Figure 2E). Furthermore, hearts
showed CD68þ cells (infiltrating macrophages)
(Figure 2F) and increased MCP-1 mRNA expression at
72 h post IR versus that in sham mice (1.49  1.0 vs.
4.1  1.8; p < 0.001). Cytokines assays performed on
plasma showed an increase in IL-1b, IL-6, IL-10, and
tumor necrosis factor (TNF)-a levels at 6 and 48 h
after IR (Figure 2G). Furthermore, adhesion of
monocytes on endothelial monolayers was signifi-
cantly increased after stimulation with recombinant
Gal-3 (Supplemental Figure 4). Twenty-eight days
after AKI, cardiac inflammation and fibrosis were
observed. mRNA expression of both CD68 and Gal-3
was increased (Figure 3A). Furthermore, CD68þ and
Gal-3þ cells (Figure 3B) and increased collagen areas
(Figures 3C and 3D) were observed.
Although cardiac function was normal during the
first 72 h, IR induced a late increase in left ventricular
diastolic diameter (Supplemental Table 1) and a
decrease in fractional shortening (Figure 3E) 28 days
after injury. At the anatomical level, kidney hyper-
trophy was observed 28 days after AKI and was not
prevented by MCP treatment (Supplemental Table 1).
Hind limb ischemia did not lead to cardiac dysfunc-
tion and injury, or changes in Gal-3 expression
(Supplemental Figure 5).bone marrow [BM]) and KOWT BM mice (Gal-3 KO mice grafted with
and sham KOWT BM mice at 28 days. Furthermore, in response to IR,
ham mice (p ¼ 0.016), whereas in WTKO BM mice, the Gal-3 increase
pared with KOWT BM mice (p < 0.001). (B to F) Interleukine (IL)-6
dhesion molecule (ICAM)-1 mRNAs expression were analyzed.
WTKO BM mice (p ¼ 0.001 for CD146, p ¼ 0.005 for MCP-1). Gal-3
d 6-fold vs WTKO BM mice (*p < 0.001 for all comparisons). (G) Sirius
e and blunted in WTKO BM mice. Computer-assisted cardiac fibrosis
ional shortening after 28 days post-IR in KOWT BM mice that was
d 28 days) (I) CD68/Gal-3 co-immunostaining performed on WTKO BM
D68 staining appeared to be more important and grouped after acute
am and IR mice. For 48 h and 28 days, n¼ 4 for sham KOWT BM mice,
ta are presented as mean  SEM and comparisons of medians were
igure 1.
FIGURE 5 Unilateral Ureteral Obstruction Leads to Cytokines Release, Cardiac Inflammation, Fibrosis and Dysfunction, Which Is Prevented in MCP Treated Mice
A
B
C D
E
Continued on the next page
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FIGURE 5 Continu
(A) Cytokine assays
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revealed an increase
n ¼ 5-8 for WT UUO
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726AKI-INDUCED CARDIAC INFLAMMATION, FIBROSIS,
AND DYSFUNCTION IS GAL-3 DEPENDENT. Inacti-
vation of Gal-3 by pharmacological inhibition (MCP
treatment) and by genetic invalidation (Gal-3 KO
mice) blunted cardiac consequences of AKI. Gal-3
inactivation prevented Gal-3 and cytokine release
(Figures 2D and 2G), as well as cardiac endothelial
activation (Figure 2H) during the first 72 h after renal
IR. At 28 days post-AKI, Gal-3 inactivation prevented
cardiac monocyte recruitment, Gal-3 increase
(Figure 3B), cardiac fibrosis, and cardiac dysfunction
(Figures 3C to 3E).
GAL-3 FROM BM-DERIVED CELLS IS RESPONSIBLE
FOR CARDIAC DAMAGE. AKI was performed in a
graft mouse model of BM. Chimeric mice were sub-
mitted to renal IR and killed 28 days post-reperfusion
(Supplemental Figures 1B and 2). No variations in
anatomical data were observed (Supplemental
Table 2). Plasma Gal-3 levels were close to zero in
sham WTKO BM mice. Furthermore, in response to
renal IR, plasma Gal-3 levels were higher in KOWT BM
than in WTKO BM mice (Figure 4A). No variation in
plasmatic IL-6 levels was observed at 28 days post-IR
(Figure 4B). Cardiac CD146 and MCP-1 mRNA
levels, an endothelial and inflammatory marker,
respectively, were lower in IR WTKO BM mice versus
KOWT BM mice (Figures 4C and 4D). Cardiac Gal-3
mRNA expression did not change between sham and
IR mice but varied according to mice genotype.
However, Gal-3 protein expression was slightly
increased at 28 days after IR (Supplemental Figure 6).
Cardiac Gal-3 mRNA expression was higher in KOWT BM
mice than in WTKO BM mice (Figure 4E). Moreover, an
increase in ICAM-1 mRNA expression was observed in
response to IR only in KOWT BM mice (Figure 4F).
Furthermore, Sirius red staining showed a
significant increase in cardiac interstitial fibrosis in
response to IR in KOWT BM mice compared with sham
mice, which was blunted in WTKO BM mice (Figure 4G).ed
performed in plasma showed a progressive increase in TNF-a, IL-6, and gal-3
OþMCP (p < 0.001 for comparisons at 28 days and 56 days) and WT sham
rdiac mRNAs increased expressions of ICAM-1, MCP-1 and gal-3 compared to
were prevented in MCP treated mice at 2 months post-surgery (for UUO vs U
Laminin immunostaining performed on cardiac tissue showed an increase in CD
ification of CD68 staining confirmed the above observations. (p ¼ 0047 for
vs sham and p ¼ 0.011 for UUO vs UUOþMCP at 2 months). (D) Sirius red co
llagen accumulation and deposition. Computer-assisted cardiac fibrosis evalua
UUOþMCP). (E) Left ventricular Fractional shortening (FS) analysis by echocar
p ¼ 0.01 for UUO vs sham), prevented in treated mice (p ¼ 0.02 for UUO vs U
in LVEDD after 2 months for UUO (p ¼ 0.043 UUO vs sham), reflecting left ven
, n ¼ 6-8 for WT UUO þ MCP. Data are presented as mean  SEM and comp
bbreviations as in Figures 1, 2, and 4.Echocardiography revealed a decrease in fractional
shortening after IR only in KOWT BM mice (Figure 4H).
Finally, CD68/Gal-3 co-staining in cardiac tissue
showed CD68þ/Gal-3þ cells in KOWT BM mice, whereas
CD68þ cells in WTKO BM mice were Gal-3 (Figure 4I).
CARDIAC DAMAGE AFTER AKI IS GAL-3 DEPENDENT
BUT RENAL FUNCTION INDEPENDENT. Next, we
assessed another model of renal injury, the unilateral
ureteral obstruction (UUO), which does not affect
renal function (Supplemental Figures 7A and 7B).
Levels of Cr and BUN remained normal after UUO,
whereas inflammation increased in the obstructed
kidney. UUOþMCP mice were protected against renal
inflammation (Supplemental Figure 7B). An increase
in tubular dilatation was observed in both UUO and
UUOþMCP mice at 15 days; an increase in right kidney
weight (i.e., renal hypertrophy) was also observed at
2 months (Supplemental Figure 7B, Supplemental
Table 3). Plasma levels of TNF-a, IL-6, IL-1b, and IL-
10 were also increased after UUO and peaked at
28 days, except for IL-1b, which rapidly increased
after surgery, peaked at 7 days, and then decreased
and returned to baseline. The increase of cytokine
levels was prevented by MCP treatment (Figure 5A,
Supplemental Figure 8). Plasma levels of Gal-3
increased progressively during the 2 months of UUO
(by 4-fold compared with sham group). In MCP-
treated mice, the plasmatic increase of Gal-3 was
blunted (Figure 5A). Similar signs of cardiac damage
were observed compared with the renal IR model. An
early (day 3) and transient cardiac increase in ICAM-1
and late (2 months) increase in ICAM-1, MCP-1, and
Gal-3 mRNA levels were observed in response to UUO,
which were all prevented by MCP treatment
(Figure 5B). At 28 days and 2 months, UUO induced
cardiac inflammation and fibrosis, as shown by
CD68þcells (Figure 5C) and by an increase of intersti-
tial collagen areas (Figure 5D). MCP treatment pre-
vented fibrosis (Figures 5C and 5D). Importantly, UUOlevels until 28 days and 2 months respectively in response to UUO
mice (p < 0.001 for comparisons at 28 days and 56 days). (B) In
sham (UUO vs sham: p < 0.001 for ICAM-1, p ¼ 0.019 for MCP-1,
UOþMCP: p ¼ 0.002 for ICAM-1, p < 0.001 for MCP-1, p ¼ 0.002
68þ cells in response to UUO from 28 days and less CD68þ cells
UUO vs sham and p ¼ 0.01 for UUO vs UUOþMCP at 28 days;
loration revealed cardiac fibrosis afterat2 months of UUO. MCP
tion confirmed these results (p < 0.001 for both comparisons UUO
diography after 2 months highlights a progressive decreasing in FS
UOþMCP). Left ventricular end diastolic diameter (LVEDD) analysis
tricular dilatation. For different time points, n ¼ 4 for WT sham UUO,
arisons of medians were made with non-parametric Mann-Whitney
FIGURE 6 Plasma Gal-3 and AKI in Critically Ill Patients Discharged From ICU
(A) Plasma Gal-3 level at hospital discharge according to AKI stage (sub-clinical, and stage 1, 2, or 3 of the KDIGO guidelines). We observed a
stepwise increase of plasma Gal-3 level with AKI stages. (B) Graphical representation of imbalance in patients’ characteristics before and after
propensity score (PS) matching between no AKI and AKI patients (Black squares represents mean standardized difference [MSD] before
PS-matching and the red points MSD after PS-matching). Abbreviations as in Figure 1.
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728induced left ventricular dilatation and a decrease in
fractional shortening, which was prevented by MCP
(Figure 5E).
AKI IS ASSOCIATED WITH GAL-3 EXPRESSION AND
CARDIAC INJURY AT ICU DISCHARGE IN THE CLIN-
ICAL SETTING. In the clinical cohort, 645 (58%) pa-
tients developed AKI during ICU stay and were
discharged alive (Supplemental Table 4), including
252 patients with subclinical AKI and 134, 65, and 194
patients with AKI KDIGO stages 1, 2, and 3, respec-
tively. Plasma level of Gal-3 showed a stepwise in-
crease with severity of AKI (from subclinical to stage
3) (Figure 6). Plasma level of Gal-3 was associated
with AKI in univariable analysis (mean difference:
8.60 ng/ml; 95% CI: 7.04 to 10.15; p < 0.001) and
remained significantly associated after adjustment
for cofounding factors in multivariable analysis
(mean difference: 5.13 ng/ml; 95% CI: 2.92 to 7.35;
p < 0.001)). AKI was associated with increased bio-
markers of cardiac injury (Gal-3, sST-2 and high-
sensitivity troponin I), increased cardiac stress
(NT-proBNP), and systemic inflammation (IL-6) at ICU
discharge, even in patients who recovered their renal
function (Supplemental Table 5).
DISCUSSION
In this study, we explored the impact of AKI on
remote cardiac injury. Results showed that renal IR
promoted the development of cardiac injury and
fibrosis in part through the activation of the Gal-3
pathway. Gal-3 originated from BM-derived cells,
including macrophages. Furthermore, by using the
UUO model of renal disease we showed that cardiac
injury occurred after renal damage even if renal
function was not affected. Altogether, our data indi-
cated that the activation of the Gal-3 pathway repre-
sents 1 of the causal links between AKI and cardiac
injury.
Our findings provided important insights into
cardiorenal syndrome type 3 or acute reno-cardiac
syndrome (AKI leading to cardiac injury) pathophys-
iology (19). We hypothesized that AKI triggers the
secretion of Gal-3, which promotes the development
of cardiac injury by generating fibrosis.
Occurrence of AKI was associated with both short-
and long-term risk of mortality in different settings
(1). Furthermore, there was increasing evidence that
AKI is associated with a risk of cardiovascular events
(3,20). Recently, Go et al. (21) explored the association
between AKI and the risk of cardiovascular events
during the year following hospital discharge. Using a
large database with propensity score matching, theyobserved that AKI was a risk factor for heart failure
during the year following discharge. Such cardiovas-
cular consequences of AKI may be causal (at least
partially) in the poor outcomes of the injury. In this
study, we explored the association between AKI and
circulating expression of Gal-3 and cardiac injury in
critically ill patients. We observed that patients who
presented with AKI during ICU stay and survived had
higher plasma Gal-3 levels at discharge, along with
high plasma levels of biomarkers of cardiac injury and
failure. Although renal function did affect the level of
natriuretic peptides and troponin, eGFR did not
appear to be the major determinant of these cardiac
biomarker levels (22). Recent data showed similar
diurnal variation in patients with and without chronic
kidney disease, which suggested that decreased
clearance is not the primary mechanism for elevated
high-sensitivity cardiac troponin levels in the pa-
tients with renal failure (23). Importantly, elevated
levels of natriuretic peptides and troponin were
associated in many studies with cardiovascular
events and outcome (24,25). Therefore, these bio-
markers are still considered valid biomarkers of car-
diovascular events in patients with renal failure.
Finally, patients with AKI but who were discharged
with eGFR >60 ml/min/1.73 m2 showed elevated
plasma biomarkers of cardiac damage compared with
patients without AKI (Supplemental Table 5).
We used preclinical models to explore the patho-
physiological roles of Gal-3 after AKI. In our models,
acute cardiac response to renal injury was character-
ized by an early increase in plasmatic cytokine levels
and cardiac injury. The acute cardiac response was
followed by a late cardiac response that was charac-
terized by systolic dysfunction and cardiac fibrosis.
The early and late cardiac responses were
Gal-3dependent because they were prevented by
MCP, a Gal-3 inhibitor, and in Gal-3 KO mice. Of note,
the role of Gal-3 in remote cardiac injury was specif-
ically linked to renal injury because hind limb IR did
not induce any cardiac damage. Furthermore, Gal-3
remained elevated both in the plasma and heart in
the preclinical models despite complete restoration of
renal function.
In short-term animal experiments, AKI was shown
to promote cellular apoptosis in the heart, followed by
cardiac hypertrophy and fibrosis. Burchill et al. (26)
observed cardiac hypertrophy and fibrosis 10 days
after renal IR. Increased levels of immunoreactive
TNF-a, IL-1, and ICAM-1 mRNA were also reported in
the heart within 48 h after renal IR (27). Furthermore,
cardiomyocyte apoptosis was also observed and
associated with cardiac dysfunction evaluated by
FIGURE 7 Schematic Representation of the Results From Initial Renal Injury to Cardiac Dysfunction, Including the Effects of Gal-3 Inhibition
Renal injury induced transient renal dysfunction only in the IR model (increase in creatinine and blood urea nitrogen), as well as tubular cell response and macrophage
activation, which led to an increase in Gal-3 expression. These features led to systemic inflammation by increasing levels of plasma cytokines (Il-1, IL-6, IL-10, and
TNF-a) and Gal-3, which induced cardiac endothelial activation as shown by increased in ICAM-1, vascular cell adhesion molecule-1, monocyte chemoattractant protein-
1 and connective tissue growth factor mRNA levels. Endothelial activation promoted monocyte infiltration in cardiac tissue; these monocytes differentiated into
activated macrophages (increased CD68), thus expressing and secreting transforming growth factor (TGF)-b and Gal-3. TGF-b and Gal-3 may participate in the
activation of fibroblasts leading to collagen type 1 and 3 synthesis and subsequent cardiac fibrosis and dysfunction. Treatment with MCP, Gal-3 deletion (Gal-3 KO
mice), and WT mice grafted with Gal-3 KO BM, prevented the increase in plasma cytokines, Gal-3, cardiac Gal-3, fibroblast activation, and the increase in cardiac fibrosis,
which therefore prevented cardiac dysfunction. Abbreviations as in Figures 1, 2, and 4.
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729echocardiography at 72 h (28). In another study, the
macrophage chemokine osteopontin was increased,
along with macrophage infiltration in the heart after
24 h of renal IR (29). In addition, increased TNF-a,
IL-6, and IL-1b plasma concentrations were observed
3 h after renal IR (30). In our model, cytokine assays
showed increased plasma cytokine levels in response
to AKI during the acute stage (6 to 48 h). This increase
was prevented in MCP-treated and Gal-3 KO mice.
Martinez-Martinez et al. (8) showed that experimental
hyperaldosteronism leads to cardiac fibrosis in a
Gal-3dependent pathway that is independent of
blood pressure (8). The results from our study showed
that AKI promoted Gal-3dependent cardiac injury
and inflammation, fibrosis, and systolic dysfunction.
Recently, macrophages were identified as key
players in the development of heart failure (31). As we
observed in our model, infiltration of macrophageswas facilitated by the activation of the endothelium
(which overexpresses its cell surface adhesion pro-
teins, intercellular adhesion molecule-1, vascular cell
adhesion molecule-1), which favored inflammatory
cells transfer from the vascular compartment to the
tissue. The role of Gal-3 as a chemokine was previously
shown by Sano et al. (32), and in addition to that study,
we showed that Gal-3 promotes monocyte adhesion
(Supplemental Figure 4). Consequently, Gal-3 might
have both chemoattractive and pro-adhesive effects
locally in the damaged tissues. Gal-3 was already
known for inducing fibrosis via the synthesis of TGF-b
(33), but also by activating fibroblasts and collagen
synthesis (34). The pro-fibrotic effect of Gal-3 was
observed separately both in the kidney and the heart,
making this lectin a serious promoter of type 3 car-
diorenal syndrome. MCP is a complex water-soluble
indigestible polysaccharide rich in b-galactose. The
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730carbohydrate chains of MCP are rich in galactose and
are recognized by Gal-3 carbohydrate recognition do-
mains. MCP’s recognized mode of action is Gal-3 ac-
tivity inhibition via carbohydrate recognition
domains. There are currently no data that show anti-
cytokinic or pro-cytokinic action of MCP via another
pathway. However, we could not confirm the speci-
ficity of the carbohydrate recognition domain pathway
mechanism of action of MCP.
AKI can induce systemic sympathetic nervous
system and renin-angiotensin-aldosterone system
activation (35). Although the increase in systemic
arterial pressure was not sustained, increased
vascular reactivity to angiotensin II was reported (36).
Our group and others showed that activation of the
renin-angiotensin-aldosterone system could promote
cardiac and renal injuries (10,11). Gal-3 participates in
the mechanisms of aldosterone-mediated myocardial
damage. It is therefore also possible that activation of
the renin-angiotensin-aldosterone system promotes
endothelial injury in remote organs after AKI. These
vascular consequences should be investigated in the
future.
Finally, cardiac fibrosis has been extensively
recognized as a key player in the development of
heart failure. In our models, cardiac expression of
Gal-3 was decreased in mice that received MCP
compared with control mice and was associated with
lower macrophage infiltration, which reflected a
possible positive feedback of Gal-3 on macrophage
recruitment. Thus, a decrease in cardiac Gal-3
expression may arise from direct synthesis inhibi-
tion as well as a decrease in macrophage recruitment.
We explored the source of Gal-3 in our models.
Gal-3 can be expressed in different cell types
including tubular and immune cells (37). In our model
of renal IR, damaged tubules expressed Gal-3 and
might also be the source of pro-inflammatory cyto-
kine expression. In this study, the question of the
source of cardiac Gal-3 after AKI was mainly explored
using BM transplantation. We showed that renal IR
led to an increase in Gal-3 expression, cardiac fibrosis,
and dysfunction in WT mice, but this damage was
prevented in WTKO BM mice. Furthermore, we
observed cardiac CD68þ/Gal-3þ cells by immuno-
staining only in KOWT BM mice, whereas WTKO BM mice
did not express cardiac Gal-3. This set of experiments
confirmed that cardiac Gal-3 arises from BM -derived
immune cells, including macrophages. Souza et al.
(38) showed in a mouse model of myocarditis that
cardiac Gal-3 expression was high in macrophages, T
cells, and fibroblasts using flux cytometry andconfocal microscopy. Inhibition of Gal-3 by MCP or N-
acetyl-D-lactosamine reduced cardiac inflammation
and fibrosis and modulated the expression of pro-
inflammatory genes in the heart.
Gal-3 appears to be a mandatory mediator for
AKI-Induced cardiac damage because a specific
blockage of the Gal-3 pathway prevented cardiac
damage and injury. Gal-3 was shown to trigger im-
mune cells and cytokines release. Inhibition of Gal-3
activity led to inhibition of macrophage recruitment
and activation, and therefore, indirectly to a
decrease in cytokine expression (e.g., TNF-a, IL-1,
IL-6, IL-4, or IL-8 (34,39). The decrease in the
expression of these cytokines led to the modulation
of other cytokines in the downstream inflammatory
cascade. Therefore, Gal-3 appeared upstream of the
release of these cytokines. However, it remains to
be tested whether blocking 1 of these downstream
cytokines (IL-1, IL-6, TNF-a) would have car-
dioprotective effects as well.
A summary scheme of our results is shown in
Figure 7. Kidney injury induces an increase in renal,
circulating, and cardiac Gal-3 expression and in
circulating cytokines levels. Kidney injury leads to
cardiac damage via endothelium activation, mono-
cyte recruitment, and finally development of cardiac
fibrosis and dysfunction. Remote cardiac conse-
quences of kidney injury are prevented in Gal-3 KO
mice, MCP-treated mice, and in WTKO BM mice.
CONCLUSIONS
The Gal-3 pathway is involved in remote cardiac
damage after AKI, which may be involved in
AKI-associated poor outcomes. Cardiac Gal-3 origi-
nates from BM -derived cells. These findings open
an area of clinical research with the aim of pre-
vention of devastating consequences of AKI in
humans.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: AKI leads
to remote cardiac injuries, including cardiac inflammation,
acute dysfunction, and in fine fibrosis. These effects may
contribute to poor outcomes after AKI. Remote cardiac
injury after AKI is in part mediated by a Gal-3dependant
pathway that originates mainly from BM-derived immune
cells.
TRANSLATIONAL OUTLOOK: Future research should
examine inhibition of the Gal-3 pathway after AKI to
prevent the adverse cardiac effects induced by AKI and to
improve its prognosis.
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